Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective

被引：0

|

作者：

Kenneth Boyd

Peter Hall

机构：

来源：

PharmacoEconomics | 2016年 / 34卷

关键词：

Everolimus; Moral Responsibility; Pertuzumab; Judicial Review; Eribulin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：529 / 531

页数：2

相关论文

共 50 条

[1] Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective
Boyd, Kenneth
Hall, Peter
PHARMACOECONOMICS, 2016, 34 (06) : 529 - 531
[2] Can we afford to ignore missing data in cost-effectiveness analyses?
Marshall, Andrea
Billingham, Lucinda J.
Bryan, Stirling
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2009, 10 (01): : 1 - 3
[3] Can we afford to ignore missing data in cost-effectiveness analyses?
Andrea Marshall
Lucinda J. Billingham
Stirling Bryan
The European Journal of Health Economics, 2009, 10 : 1 - 3
[4] You probably can't afford it, but can you afford to ignore it?
Hazlerigg, D
JOURNAL OF NEUROENDOCRINOLOGY, 2003, 15 (10) : 905 - 906
[5] CAN WE AFFORD TO IGNORE THE NEGRO
PARKER, TF
LIBRARY JOURNAL, 1963, 88 (22) : 4716 - 4717
[6] Can India afford to ignore biotechnological applications?
Zehr, UB
VILLAGES IN THE FUTURE: CROPS, JOBS AND LIVELIHOOD, 2001, : 339 - 344
[7] CAN YOU AFFORD TO IGNORE ANALOGUE MODULES
GLEDHILL, B
ELECTRONIC ENGINEERING, 1970, 42 (505): : 63 - &
[8] 'A challenge we can no longer afford to ignore'
Peter Aldous
British Dental Journal, 2022, 232 (1) : 12 - 12
[9] Can clinicians afford to ignore molecular medicine?
Naresh, KN
NATIONAL MEDICAL JOURNAL OF INDIA, 2000, 13 (05): : 225 - 227
[10] CAN YOU AFFORD TO IGNORE NETWORK MANAGEMENT
KING, LH
DATA PROCESSING, 1982, 24 (01): : 17 - 18

← 1 2 3 4 5 →